Filtered By:
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 256 results found since Jan 2013.
Immunogenicity and safety of Havisure < sup > TM < /sup > vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study
CONCLUSION: The study results indicate that the Havisure™ vaccine is immunogenic and safe when administered to healthy subjects of 12 months to 49 years of age, and is non-inferior to Havrix® Vaccine.PMID:37661535 | DOI:10.1016/j.vaccine.2023.08.084
Source: Vaccine - September 4, 2023 Category: Allergy & Immunology Authors: Sai Krishna Susarla Madhu Gupta Kheya Ghosh Uttam Sonali Palkar Ashish Ramachandra Dhongade K Siva Ram Prasad Vasudev Rajapantula M D Ravi N Pradeep M Satish B C Rajashakar G Sandhya L Rajendra Devi Prasad Sahoo Anand Kumar Kanakasapapathy Source Type: research
Gastrointestinal tract and viral pathogens
World J Virol. 2023 Jun 25;12(3):136-150. doi: 10.5501/wjv.v12.i3.136.ABSTRACTViral gastroenteritis is the most common viral illness that affects the gastrointestinal (GI) tract, causing inflammation and irritation of the lining of the stomach and intestines. Common signs and symptoms associated with this condition include abdominal pain, diarrhea, and dehydration. The infections commonly involved in viral gastroenteritis are rotavirus, norovirus, and adenovirus, which spread through the fecal-oral and contact routes and cause non-bloody diarrhea. These infections can affect both immunocompetent and immunocompromised indiv...
Source: Herpes - July 3, 2023 Category: Infectious Diseases Authors: Gowthami Sai Kogilathota Jagirdhar Yashwitha Sai Pulakurthi Himaja Dutt Chigurupati Salim Surani Source Type: research
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
A randomized, controlled Phase 1b trial of the < i > Sm < /i > -TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area
ConclusionsVaccination of adults withSm-TSP-2/Alhydrogel in an area of ongoingS.mansoni transmission was safe, minimally reactogenic, and elicited significant IgG and IgG subclass responses against the vaccine antigen. These promising results have led to initiation of a Phase 2 clinical trial of this vaccine in an endemic region of Uganda. Trial registrationNCT03110757.
Source: PLoS Neglected Tropical Diseases - March 30, 2023 Category: Tropical Medicine Authors: David J. Diemert Source Type: research
Assessment of risk factors associated with outbreak of hepatitis A in Shakrial, Rawalpindi, Pakistan
Conclusions: Healthcare departments should implement public policies towards the management of hepatitis A in Pakistan. Health awareness sessions and vaccination for children ≤ 16 years age is recommended.
Source: The Journal of Infection in Developing Countries - January 31, 2023 Category: Infectious Diseases Authors: Aamir Badar, Muhammad Wasif Malik, Syed Zain Hasnain, Syed Ijaz Ali Shah, Rana Muhammad Kamran Shabbir, Waseem Haider, Haroon Ahmed Source Type: research
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Pain at Hepatitis B Vaccine in Preterm Infants
Condition: Infant, Newborn, Pain Intervention: Behavioral: Palmar grasp reflex Sponsors: Ataturk University; MSc Elif Simay KOÇ Recruiting
Source: ClinicalTrials.gov - January 5, 2023 Category: Research Source Type: clinical trials
